Bromopride API Manufacturers

Looking for Bromopride API 4093-35-0?

Description:

Here you will find a list of producers, manufacturers and traders of Bromopride. You can sort by certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.

API | Excipient name:

Bromopride 

Synonyms:

Bromoprid , Bromoprida , Bromopride , Bromopridum  

Cas Number:

4093-35-0 

DrugBank number:

DB09018 

Unique Ingredient Identifier:

75473V2YZK

Bromopride is a type of Dopamine antagonists

Dopamine antagonists belong to the pharmaceutical API subcategory that plays a crucial role in the management of various medical conditions. These compounds act by blocking dopamine receptors, which are responsible for transmitting signals in the brain. By inhibiting dopamine activity, dopamine antagonists exhibit diverse therapeutic effects.

One significant application of dopamine antagonists is in the treatment of psychiatric disorders. They are commonly used to manage schizophrenia, a severe mental disorder characterized by hallucinations, delusions, and disorganized thinking. Dopamine antagonists help reduce the symptoms of schizophrenia by normalizing the excessive dopamine activity in the brain.

Additionally, these pharmaceutical APIs find application in managing other conditions such as bipolar disorder, nausea, vomiting, and certain movement disorders. Dopamine antagonists can effectively alleviate the symptoms associated with these conditions by modulating dopamine levels and restoring the balance in neural signaling.

Pharmaceutical companies utilize advanced synthesis and purification techniques to produce high-quality dopamine antagonists for use as active ingredients in various medications. These APIs undergo stringent quality control measures to ensure their safety, efficacy, and compliance with regulatory standards.

In conclusion, dopamine antagonists constitute an important subcategory of pharmaceutical APIs, offering valuable therapeutic benefits for psychiatric disorders, nausea, vomiting, and movement disorders. Their ability to selectively block dopamine receptors makes them indispensable in modern medicine, enabling improved patient outcomes and quality of life.

Bromopride (Dopamine antagonists), classified under Central Nervous System Agents

Central Nervous System (CNS) Agents are a crucial category of pharmaceutical Active Pharmaceutical Ingredients (APIs) that specifically target the central nervous system. The CNS encompasses the brain and spinal cord, playing a vital role in regulating and controlling various bodily functions, including cognition, movement, emotions, and sensory perception. These agents are designed to interact with specific receptors, enzymes, or ion channels within the CNS to modulate neural activity and restore normal functioning.

CNS agents comprise a diverse range of pharmaceutical APIs, including analgesics, anesthetics, antipsychotics, sedatives, hypnotics, anti-epileptics, and antidepressants. Each subcategory addresses distinct neurological disorders and conditions. For instance, analgesics alleviate pain by targeting receptors in the brain and spinal cord, while antipsychotics are employed to manage psychosis symptoms in mental illnesses such as schizophrenia.

The development of CNS agents involves rigorous research, molecular modeling, and extensive clinical trials to ensure safety, efficacy, and specific target engagement. Pharmaceutical companies invest significant resources in identifying novel drug targets, synthesizing new compounds, and optimizing their pharmacological properties. These agents undergo rigorous regulatory evaluations and must adhere to stringent quality standards and guidelines.

Given the prevalence of CNS disorders globally, the market demand for effective CNS agents is substantial. The development of innovative CNS APIs not only improves patient outcomes but also provides valuable commercial opportunities for pharmaceutical companies. Continued advancements in CNS agent research and development hold the promise of groundbreaking therapies that can improve the quality of life for individuals affected by neurological conditions.

• LEBSA from Spain, product country of origin Spain
• ICROM from Italy, product country of origin Italy

Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.

You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.